Amplia Therapeutics Reports Increased Losses Amid Revenue Decline

Amplia Therapeutics Ltd. (AU:ATX) has released an update.

Amplia Therapeutics Limited has reported a significant 149% increase in losses for the half-year ending September 2024, totaling $2.8 million, while revenues fell by 41% to approximately $1.5 million. Despite these challenges, the company remains focused on developing its pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, with no dividends declared for the period.

For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.